Current Report Filing (8-k)
July 09 2015 - 8:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 9, 2015
CORTEX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S
Employer
Identification
No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
|
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Item
7.01 Regulation FD Disclosure
Cortex
Pharmaceuticals, Inc. (the “Company”) has previously furnished via Current Reports on Form 8-K iterations of a
slide presentation that it has also posted and updated on its website and shared with various interested parties and
presented at conferences and in other contexts. The most recent version of this presentation was filed on a Current Report on
Form 8-K/A filed May 18, 2015. Since that filing, the Company’s plans have continued to develop and the Company has
accordingly decided to update the slide presentation, specifically to reflect the revised anticipated timing of certain
milestones and targets listed therein, in connection with its attendance at the National Angel-VC Summit & Growth Capital
Forum being hosted at the Yale Club New York on July 9, 2015. At that forum, and thereafter, the Company may provide the
updated slide presentation to interested parties. The updated slide presentation will also be available on the
Company’s website.
The
updated slide presentation that the Company will be using at the conference is attached as Exhibit 99.1 and is being furnished
and not filed pursuant to Item 7.01 of Form 8-K.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: July 9, 2015 |
CORTEX PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/
Arnold S. Lippa |
|
|
Arnold S. Lippa
President and Chief
Executive Officer |
EXHIBIT
INDEX
Exhibit
Number |
|
Exhibit
Description |
|
|
|
99.1 |
|
Slide Presentation (furnished herewith). |
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024